Deliberate infection trial finds COVID symptoms dont indicate viral shedding – Reuters

A 3D-printed coronavirus model is seen in front of the words coronavirus disease (Covid-19) on display in this illustration taken March 25, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

Register now for FREE unlimited access to Reuters.com

April 1 (Reuters) – The world’s first “human challenge” trial in which volunteers were deliberately exposed to the coronavirus has found that symptoms had no effect on how likely an infected person is to pass the disease on to others.

The findings underscore the difficulty in preventing community infections as the Word Health Organization (WHO) warns of a rise in cases.

The research project, run by Open Orphan (ORPH.L) with Imperial College, London, showed that among the 18 participants that caught COVID-19, the severity of symptoms, or whether they developed symptoms at all, had nothing to do with the viral load in their airways. read more

Register now for FREE unlimited access to Reuters.com

The viral load, or tendency to shed the virus, was measured by two methods known as focus-forming assay (FFA) and quantitative polymerase chain reaction (qPCR).

“There was no correlation between the amount of viral shedding by qPCR or FFA and symptom score,” the researchers said in paper published by scientific journal Nature Medicine.

The Imperial trial exposed 36 healthy young adults without a history of infection or vaccination to the original SARS-CoV-2 strain of the virus and monitored them in a quarantined setting. read more

Since two volunteers were found to have had antibodies against the virus after all, they were excluded from the analysis. Slightly more than half of them contracted the virus.

No serious adverse events occurred, and the human challenge study model was shown to be safe and well tolerated in healthy young adults, the research team had said earlier this year.

Register now for FREE unlimited access to Reuters.com

Reporting by Ludwig Burger;
Editing by Robert Birsel

Our Standards: The Thomson Reuters Trust Principles.